Publications by authors named "Sarah A Griffith"
To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1.
Front Immunol
December 2021
Since their discovery, antibodies capable of broad neutralisation have been at the forefront of HIV-1 research and are of particular interest due to passive transfer studies demonstrating their potential to provide protection. Currently an exact definition of what is required for a monoclonal antibody to be classed as a broadly neutralising antibody (bnAb) has not yet been established. This has led to hundreds of antibodies with varying neutralisation breadth being studied and has given insight into antibody maturation pathways and epitopes targeted.
View Article and Find Full Text PDFMultiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines show protective efficacy, which is most likely mediated by neutralizing antibodies recognizing the viral entry protein, spike. Because new SARS-CoV-2 variants are emerging rapidly, as exemplified by the B.1.
View Article and Find Full Text PDFArticle Synopsis
- The London patient, who underwent stem-cell transplantation with CCR5-negative cells, maintained remission from HIV-1 for 30 months after stopping treatment, with undetectable viral loads in various body fluids.
- Researchers used advanced testing methods to analyze blood, semen, cerebrospinal fluid, gut biopsies, and lymph nodes for HIV-1 presence and immune responses.
- While the patient showed some very low positive signals for HIV-1 DNA in specific immune cells, the majority of tests returned negative results, suggesting a successful and sustained response to the treatment.